secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001650664-23-000038
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas licenses Cas9 to Vertex for CASGEVY; receives $50M upfront, extends runway to 2026
--------------------------------------------------------------------------------

- Vertex gets non-exclusive Cas9 license for ex vivo BCL11A targeting sickle cell disease and beta thalassemia, including CASGEVY.
- Editas receives $50M upfront cash, $50M contingent upfront, and annual license fees of $10M-$40M through 2034.
- Editas must pay Broad Institute and Harvard a mid-double-digit percentage of amounts received from Vertex under the license.
- Cash runway extended into 2026, combining existing cash with upfront and near-term fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000038/0001650664-23-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000038/edit-20231212.htm
  HTML page:      https://secwatch.observer/filing/0001650664-23-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer